8-K: C4 Therapeutics Q3 2025: Cemsidomide Data & Extended Runway

C4 Therapeutics reported Q3 2025 financial results, highlighted positive cemsidomide Phase 1 data in multiple myeloma, and secured $125 million in gross proceeds extending its cash runway to late 2028.

Summary

• Total revenue for the third quarter of 2025 was $11.2 million, a decrease from $15.4 million in Q3 2024.
• Net loss for Q3 2025 increased to $32.2 million, compared to $24.7 million in Q3 2024.
• Cash, cash equivalents, and marketable securities were $199.8 million as of September 30, 2025, with an additional $125 million in gross proceeds from an equity offering in October 2025.
• The company's cash runway is now extended to the end of 2028.
• Phase 1 data for cemsidomide in multiple myeloma demonstrated a 53% Overall Response Rate (ORR) at the highest dose level (100g) and a median Duration of Response (DoR) of 9.3 months.
• A clinical trial collaboration and supply agreement was entered into with Pfizer to evaluate cemsidomide in combination with elranatamab.
• C4 Therapeutics is on track to initiate the registrational Phase 2 MOMENTUM trial in Q1 2026 and a Phase 1b trial in combination with elranatamab in Q2 2026.
• Merck decided to conclude its research collaboration with C4 Therapeutics, which will end in late November 2025.
• A $2 million milestone payment was earned from Biogen related to a patient dosing milestone for the Phase 1 trial of BIIB142.

Sentiment

Score: 7

Explanation: The strong clinical data for cemsidomide, successful capital raise extending the cash runway, and strategic collaboration with Pfizer are significant positives. The increased net loss and termination of the Merck collaboration are minor drawbacks but are overshadowed by the clinical and financial progress, indicating a generally positive outlook for the company's pipeline and financial stability.

Positives

• Successfully completed an equity offering, raising $125 million in gross proceeds, with potential for up to an additional $225 million from outstanding warrants.
• Extended cash runway to the end of 2028, providing financial stability beyond key clinical data readouts.
• Cemsidomide Phase 1 data in multiple myeloma showed a compelling 53% Overall Response Rate (ORR) at the 100g dose level and 40% at 75g in heavily pre-treated patients.
• Cemsidomide demonstrated a differentiated safety and tolerability profile and a median Duration of Response of 9.3 months.
• One patient at the 100g dose level achieved a minimal residual disease (MRD) negative complete response with cemsidomide.
• Entered into a clinical trial collaboration and supply agreement with Pfizer, with Pfizer supplying elranatamab at no cost for the upcoming Phase 1b trial.
• On track to initiate the registrational Phase 2 MOMENTUM trial in Q1 2026 and a Phase 1b trial in combination with elranatamab in Q2 2026.
• CFT8919 Phase 1 dose escalation trial is advancing in Greater China through partner Betta Pharmaceuticals.
• Earned a $2 million milestone payment from Biogen for the Phase 1 trial of BIIB142.

Negatives

• Net loss for Q3 2025 increased to $32.2 million, compared to $24.7 million for Q3 2024.
• Total revenue for Q3 2025 decreased to $11.2 million from $15.4 million in Q3 2024, primarily due to an $8.0 million milestone from Biogen recognized in Q3 2024.
• Merck notified the company of its decision to conclude the research collaboration, which will end in late November 2025.
• Cash, cash equivalents and marketable securities decreased from $267.3 million as of December 31, 2024, to $199.8 million as of September 30, 2025, prior to the recent equity offering.

Risks

• Uncertainties related to the initiation, timing, advancement, and conduct of preclinical and clinical studies and other development requirements for product candidates.
• Risk that any one or more product candidates will cost more to develop or may not be successfully developed and commercialized.
• Risk that sufficient capital to fund future operations will not be available on acceptable terms or at the times required.
• Inability to replicate results achieved in preclinical studies or clinical trials in any future studies or trials.
• Inability to replicate interim or early-stage results from clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials.
• Regulatory developments in the United States and foreign countries could impact product development and approval.

Future Outlook

The company expects its current cash, cash equivalents, and marketable securities, including the recent $125 million equity raise, to fund its operating plan until the end of 2028. It is on track to formally align with the FDA on the recommended Phase 2 dose of cemsidomide by year-end 2025. The initiation of the registrational Phase 2 MOMENTUM trial for cemsidomide in combination with dexamethasone is expected in Q1 2026, and a Phase 1b trial for cemsidomide in combination with elranatamab is expected to initiate in Q2 2026.

Management Comments

• "Recent months have been transformative for C4T, and we are in a strong position to rapidly advance cemsidomide registrational development and progress our discovery pipeline of degraders against non-oncology and oncology targets."
• "We remain laser-focused on initiating cemsidomide’s next phase of development in early 2026, which includes a Phase 1b trial in combination with elranatamab as well as the Phase 2 MOMENTUM trial in combination with dexamethasone, which has potential for accelerated approval."
• "With a successful raise of $125 million in upfront proceeds, we have extended our runway to the end of 2028, beyond important data from cemsidomide’s Phase 2 trial with dexamethasone and the Phase 1b in combination with elranatamab, strengthening our balance sheet to continue to deliver on the promise of targeted protein degradation to improve patients’ lives."

Industry Context

C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a novel therapeutic modality. The positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, positions it as a potential best-in-class candidate in the competitive multiple myeloma landscape, particularly given its differentiated safety and efficacy profile in heavily pre-treated patients. The collaboration with Pfizer for elranatamab, a BCMAxCD3 bispecific antibody, aligns with the industry trend of developing combination therapies to enhance outcomes in relapsed/refractory multiple myeloma. The conclusion of the Merck collaboration, while a negative, is not uncommon in early-stage drug discovery partnerships, reflecting the high-risk, high-reward nature of the biopharmaceutical sector.

Comparison to Industry Standards

• Cemsidomide's 53% Overall Response Rate (ORR) at the 100g dose level and 40% at 75g, coupled with a median Duration of Response (DoR) of 9.3 months in heavily pre-treated multiple myeloma patients, suggests a competitive profile compared to other IKZF1/3 degraders in similar patient populations.
• The achievement of a minimal residual disease (MRD) negative complete response in one patient at the 100g dose level is a strong indicator of deep and durable response, which is a key benchmark for efficacy in multiple myeloma treatment.
• The clinical trial collaboration with Pfizer to evaluate cemsidomide in combination with elranatamab (ELREXFIO), a B-cell maturation antigen CD3 targeted bispecific antibody, aligns with industry trends of combining novel mechanisms of action to enhance therapeutic outcomes in relapsed/refractory multiple myeloma. Elranatamab itself has demonstrated strong efficacy in heavily pre-treated MM patients, and its combination with cemsidomide aims to build upon this, potentially offering a new standard of care.

Stakeholder Impact

• Shareholders: Positive impact due to extended cash runway, strong clinical data, and strategic partnerships, potentially reducing near-term dilution risk and increasing long-term value proposition.
• Patients: Potential for new, effective treatment options for relapsed/refractory multiple myeloma and other difficult-to-treat diseases through cemsidomide and other pipeline candidates.
• Employees: Continued stability and focus on advancing pipeline programs with extended financial runway.
• Partners (Pfizer, Betta Pharmaceuticals): Strengthened collaborations and continued progress on joint development efforts.
• Partners (Merck): Collaboration concluded, which may free up resources for other internal or partnered programs.

Next Steps

• Formally align with the U.S. Food & Drug Administration (FDA) on the recommended Phase 2 dose of cemsidomide for the registrational Phase 2 trial by year-end 2025.
• Initiate a Phase 2 single-arm registrational trial of cemsidomide in combination with dexamethasone in Q1 2026.
• Initiate a Phase 1b trial of cemsidomide in combination with elranatamab in Q2 2026.
• Management will participate in a fireside chat at the Guggenheim Second Annual Healthcare Conference on November 12, 2025.
• Management will participate in a fireside chat at the 8th Evercore Healthcare Conference on December 3, 2025.

Key Dates

Recommendation

While the clinical data for cemsidomide is promising and the capital raise significantly extends the cash runway, the company is still in clinical development with no approved products. The increased net loss and termination of the Merck collaboration are minor concerns. The stock is likely to be sensitive to future clinical trial readouts and regulatory milestones. A 'Hold' recommendation reflects the balance between strong progress and inherent risks of a clinical-stage biopharmaceutical company, suggesting investors monitor upcoming data and regulatory interactions closely.

Keywords

C4 Therapeutics, CCCC, targeted protein degradation, cemsidomide, multiple myeloma, elranatamab, dexamethasone, MOMENTUM trial, CFT8919, non-small cell lung cancer, EGFR, BiDAC, MonoDAC, Biogen, Pfizer, Merck, clinical trial, financial results, Q3 2025, equity offering, cash runway, biopharmaceutical, oncology